* Portfolio
          * About
          * Team
          * News
          * Careers
          * Contact
          * LP Login

      Early growth equity for rapidly-scaling B2B software and healthcare companies

      Partnering with exceptional teams since 1983

        CEO SPOTLIGHTS

          We partner with strong CEOs of high-growth businesses, and together we scale.

            Delivering managed detection and response (MDR) across the enterprise.
            READ MORE

            Above all, I genuinely believe that NMP cares about the team and the company’s success. It’s not just about the return we generate. I can’t overstate how much that trust matters.

              Brian Beyer

              CEO and co-founder of Red Canary

            Offering best in class infusion therapy in under-served markets.
            READ MORE

            If I started another company, NMP is the first investor I would call.

              Gus De Avillez

              CEO of Medix Infusion

            Solving complex pricing challenges with next-generation revenue management software.
            READ MORE

            NMP has added tremendous value beyond capital. They helped us put together a board of operators with $1B+ exits, guided us on our transition from services to SaaS, and supported us through the pandemic.

              Dax Cross

              Co-founder of Revenue Analytics

            Delivering comprehensive care at home.
            READ MORE

            A lot of firms focused on the “buzz” while Noro-Moseley was focused on developing a sustainable economic model and a scalable, successful business.

              Travis Messina

              Former CEO of Contessa

          Our Exits

            Our exits represent over $ 4 billion in aggregate enterprise value since 2015

        acquired by

        acquired by

        acquired by

        acquired by

        acquired by

        acquired by

        acquired by

        acquired by

        acquired by

        acquired by

      NMP Investment Criteria

      We are actively investing in businesses that meet these key criteria

          * Year-over-year growth

            50%+

          * Compelling unit economics

          * Target revenue run rate

            $ 2M-20M

          * nmp target investment

            $ 5-20m

          * SIGNIFICANT OPPORTUNITY FOR MARKET DISRUPTION

          * Minimal prior funding

            < $ 20M

        NMP Portfolio News

        view all news
          * April 24, 2025

            A Tariff Crisis Is A Terrible Thing To Waste: Pricing And Profits

          * April 16, 2025

            Liminal Raises $ 8.5M Series A to Build the Intelligence Platform for Complex Markets and Regulated Industries

          * December 12, 2024

            Red Canary Delivers Record Q3, Maintaining Customer-Validated 99% Threat Accuracy at Scale

          * August 13, 2024

            Upward Health Ranks No. 6 on the 2024 Inc. 5000

          * August 2, 2024

            SPS Commerce Acquires SupplyPike

          * July 25, 2024

            QuVa Pharma Completes Acquisition of LogicStream Health

      view all news
          * Portfolio
          * About
          * Team
          * News
          * Careers
          * Contact
          * LP Login
        * ©2024 Noro-Moseley Partners. All Rights Reserved.
        * 

          * The Medici Building

            3284 Northside Parkway, NW
            Suite 525
            Atlanta, Georgia 30327-2337

            Directions | Direct: 404.233.1966